Form 4: Iteos Therapeutics Director Acquires Stock Options
SEC Form 4
Director David K. Lee acquired 24,200 stock options in Iteos Therapeutics, Inc. on June 11, 2024.
Summary
- David K. Lee, a director of Iteos Therapeutics, Inc., reported a transaction on June 11, 2024.
- Lee acquired 24,200 stock options with an exercise price of $16.32.
- The options become exercisable on June 11, 2025, and expire on June 11, 2034.
- Following the transaction, Lee directly owns 24,200 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option acquisition, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: acquisition of stock options. |
| 06/11/2025 | Stock options become exercisable. |
| 06/11/2034 | Stock options expiration date. |
| 06/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.